Cargando…
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study
BACKGROUND: Penile cancer (PC) is a rare tumor, and therapeutic options are limited for this disease, with an overall 5-year overall survival around 65-70%. Adjuvant therapy is not recommended for patients with N0-1 disease, despite up to 60% of these patients will die within 5 years from diagnosis....
Autores principales: | Di Lorenzo, Giuseppe, Perdonà, Sisto, Buonerba, Carlo, Sonpavde, Guru, Gigantino, Vincenzo, Pannone, Giuseppe, Quarto, Giuseppe, Ferro, Matteo, Gaudioso, Gabriella, Terracciano, Daniela, Di Trolio, Rossella, Rescigno, Pasquale, Botti, Gerardo, De Placido, Sabino, Facchini, Gaetano, Ascierto, Paolo A, Franco, Renato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717121/ https://www.ncbi.nlm.nih.gov/pubmed/23819610 http://dx.doi.org/10.1186/1479-5876-11-161 |
Ejemplares similares
-
Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021) -
The evolving landscape in advanced penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2015) -
Immunotherapy for penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2017) -
Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2015) -
Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study
por: Buonerba, Carlo, et al.
Publicado: (2016)